The COVID-19 pandemic has brought aerosol-related diseases to the forefront of the healthcare conversation. Health systems and GI practices alike continue to grapple with the best ways to diagnose and treat patients in a specialized, affordable, and safe manner. As telehealth and virtual visits become a mainstay in the healthcare delivery model, so must the consideration of at-home diagnostics, especially for aerosol-generating procedures like GI breath testing.
During a 30-minute virtual fireside chat, Dr. Ziad Gellad (Duke University School of Medicine and Duke University Medical Center) discussed his experience shifting from a point-of-care breath test model to at-home breath testing during the pandemic. Moderated by Craig S. Strasnick, President & CEO of CDI, Dr. Gellad also weighed in on both the clinical and financial impact on GI practices.